100343-19-9

Downstream Products

• 134160-30-8 2',4'-di-O-benzyl-4'',6''-O-cyclohexylidene-3'-deoxy-3'-fluoro-1,3,3''-tri-N-tosylkanamycin A 
• 100429-65-0 3'-deoxy-3'-fluorokanamycin A monocarbonate 
• 134160-31-9 2',4'-di-O-benzyl-4'',6''-O-cyclohexylidene-3'-deoxy-3'-fluoro-1,3,6',3''-tetra-N-tosylkanamycin A 

Relevant academic research and scientific papers

Synthesis of 3'-deoxy-3'-fluorokanamycin A and 3',4'-dideoxy-3'-fluorokanamycin A

3'-Deoxy-3'-fluorokanamycin A (14) has been prepared by condensation of 6-azido-2,4-di-O-benzyl-3,6-dideoxy-3-fluoro-α-D-glucopyranosyl bromide (8) and 6-O-(2-O-acetyl-4,6-O-cyclohexylidene-3-deoxy-3-tosylamino-α-D-glucopyranosyl)-2-deoxy-1,3-di-N-tosylst

3'-fluoro-3'-deoxykanamycin A

A new compound, 3'-fluoro-3'-deoxykanamycin A is now provided, which is active against gram-negative and gram-positive bacteria, including kanamycin-resistant strains of bacteria and is useful as antibacterial agent for therapeutic treatment of bacterial infections. This new compound is produced by a process comprising reacting a 6-azido-2,4-di-O-protected-3,6-dideoxy-3-fluoro-α-D-glucopyranosyl bromide with the 4-hydroxyl group of a 6-O-(2'-O-protected-3'-N-protected-3'-amino-4',6'-di-O-protected-3'-deoxy-α-D-glucopyranosyl)-1,3-bis-N-protected-2-deoxystreptamine, reducing the azido group of the resulting reaction product into an amino group, and removing the remaining protective groups from the reduction product.